Table 4 Open in new tab The results of...

Factors

5-year cumulative incidences in cardiac events of ≥Grade 3

P value

LV Mean dose

≥17.6 Gy

18.2% (95% CI, 4.58–50.7%)

0.321

<17.6 Gy

10.0% (95% CI, 1.39–46.7%)

LV V5

≥53.6%

19.2% (95% CI, 4.81–52.8%)

0.914

<53.6%

10.0% (95% CI, 1.39–46.7%)

LV V10

≥36.5%

14.3% (95% CI, 3.60–42.7%)

0.707

<36.5%

14.3% (95% CI, 1.97–58.1%)

LV V15

≥33.3%

16.1% (95% CI, 4.03–46.6%)

0.529

<33.3%

12.5% (95% CI, 1.73–53.7%)

LV V20

≥31.8%

15.4% (95% CI, 3.87–45.1%)

0.541

<31.8%

12.5% (95% CI, 1.72–53.7%)

LV V25

≥29.5%

16.1% (95% CI, 4.03–46.6%)

0.397

<29.5%

12.5% (95% CI, 1.73–53.7%)

LV V30

≥25.8%

15.4% (95% CI, 3.87–45.1%)

0.541

<25.8%

12.5% (95% CI, 1.72–53.7%)

LV V35

≥23.4%

16.1% (95% CI, 4.03–46.6%)

0.529

<23.4%

12.5% (95% CI, 1.73–53.7%)

LV V40

≥12.5%

18.2% (95% CI, 4.58–50.7%)

0.275

<12.5%

10.0% (95% CI, 1.39–46.7%)

LV V45

≥2.1%

28.4% (95% CI, 9.36–60.4%)

0.013

<2.1%

LV V50

≥1.3%

23.1% (95% CI, 7.63–52.2%)

0.06

<1.3%

LV V55

≥0.8%

21.3% (95% CI, 5.32–56.5%)

0.127

<0.8%

9.09% (95% CI, 1.26–43.9%)

LV V60

≥2.8%

0.787

<2.8%

17.8% (95% CI, 5.81–43.1%)

RT-induced myocardial damage

Yes

30.0% (95% CI, 10.0–62.4%)

0.015

Table 4

Open in new tab

The results of univariate analysis in cumulative incidences in cardiac events of Grade 3 or higher using RT-induced myocardial damage and LV dose-volume parameters

Factors		5-year cumulative incidences in cardiac events of ≥Grade 3	P value
LV Mean dose	≥17.6 Gy	18.2% (95% CI, 4.58–50.7%)	0.321
	<17.6 Gy	10.0% (95% CI, 1.39–46.7%)
LV V5	≥53.6%	19.2% (95% CI, 4.81–52.8%)	0.914
	<53.6%	10.0% (95% CI, 1.39–46.7%)
LV V10	≥36.5%	14.3% (95% CI, 3.60–42.7%)	0.707
	<36.5%	14.3% (95% CI, 1.97–58.1%)
LV V15	≥33.3%	16.1% (95% CI, 4.03–46.6%)	0.529
	<33.3%	12.5% (95% CI, 1.73–53.7%)
LV V20	≥31.8%	15.4% (95% CI, 3.87–45.1%)	0.541
	<31.8%	12.5% (95% CI, 1.72–53.7%)
LV V25	≥29.5%	16.1% (95% CI, 4.03–46.6%)	0.397
	<29.5%	12.5% (95% CI, 1.73–53.7%)
LV V30	≥25.8%	15.4% (95% CI, 3.87–45.1%)	0.541
	<25.8%	12.5% (95% CI, 1.72–53.7%)
LV V35	≥23.4%	16.1% (95% CI, 4.03–46.6%)	0.529
	<23.4%	12.5% (95% CI, 1.73–53.7%)
LV V40	≥12.5%	18.2% (95% CI, 4.58–50.7%)	0.275
	<12.5%	10.0% (95% CI, 1.39–46.7%)
LV V45	≥2.1%	28.4% (95% CI, 9.36–60.4%)	0.013
	<2.1%	0%
LV V50	≥1.3%	23.1% (95% CI, 7.63–52.2%)	0.06
	<1.3%	0%
LV V55	≥0.8%	21.3% (95% CI, 5.32–56.5%)	0.127
	<0.8%	9.09% (95% CI, 1.26–43.9%)
LV V60	≥2.8%	0%	0.787
	<2.8%	17.8% (95% CI, 5.81–43.1%)
RT-induced myocardial damage	Yes	30.0% (95% CI, 10.0–62.4%)	0.015
	No	0%

Factors		5-year cumulative incidences in cardiac events of ≥Grade 3	P value
LV Mean dose	≥17.6 Gy	18.2% (95% CI, 4.58–50.7%)	0.321
	<17.6 Gy	10.0% (95% CI, 1.39–46.7%)
LV V5	≥53.6%	19.2% (95% CI, 4.81–52.8%)	0.914
	<53.6%	10.0% (95% CI, 1.39–46.7%)
LV V10	≥36.5%	14.3% (95% CI, 3.60–42.7%)	0.707
	<36.5%	14.3% (95% CI, 1.97–58.1%)
LV V15	≥33.3%	16.1% (95% CI, 4.03–46.6%)	0.529
	<33.3%	12.5% (95% CI, 1.73–53.7%)
LV V20	≥31.8%	15.4% (95% CI, 3.87–45.1%)	0.541
	<31.8%	12.5% (95% CI, 1.72–53.7%)
LV V25	≥29.5%	16.1% (95% CI, 4.03–46.6%)	0.397
	<29.5%	12.5% (95% CI, 1.73–53.7%)
LV V30	≥25.8%	15.4% (95% CI, 3.87–45.1%)	0.541
	<25.8%	12.5% (95% CI, 1.72–53.7%)
LV V35	≥23.4%	16.1% (95% CI, 4.03–46.6%)	0.529
	<23.4%	12.5% (95% CI, 1.73–53.7%)
LV V40	≥12.5%	18.2% (95% CI, 4.58–50.7%)	0.275
	<12.5%	10.0% (95% CI, 1.39–46.7%)
LV V45	≥2.1%	28.4% (95% CI, 9.36–60.4%)	0.013
	<2.1%	0%
LV V50	≥1.3%	23.1% (95% CI, 7.63–52.2%)	0.06
	<1.3%	0%
LV V55	≥0.8%	21.3% (95% CI, 5.32–56.5%)	0.127
	<0.8%	9.09% (95% CI, 1.26–43.9%)
LV V60	≥2.8%	0%	0.787
	<2.8%	17.8% (95% CI, 5.81–43.1%)
RT-induced myocardial damage	Yes	30.0% (95% CI, 10.0–62.4%)	0.015
	No	0%

PS = performance status; BMI = body mass index. The significant P values are presented in bold font.

This Feature Is Available To Subscribers Only